A groundbreaking vaccine named ETVAX has been developed to protect children from enterotoxigenic Escherichia coli (ETEC), a toxic strain of E. coli bacteria that causes severe diarrheal illness, particularly in young children living in low-income countries. This advancement marks a significant milestone in the fight against one of the leading causes of childhood diarrhea and deaths worldwide.
ETEC infections are notorious for causing travelers’ diarrhea and are a persistent health threat in many developing regions. Children under five years of age are especially vulnerable, as their immune systems are still maturing. In these young populations, ETEC infections not only cause acute illness but can lead to malnutrition and long-term health complications. Tragically, these infections are responsible for up to 42,000 deaths annually among children in poorer countries, highlighting the urgent need for effective preventive measures.
The vaccine ETVAX was recently evaluated in a large-scale clinical trial conducted in The Gambia, involving nearly 5,000 children aged six to eighteen months. This trial is the first of its kind to assess the safety and effectiveness of an ETEC vaccine in such a substantial pediatric cohort. The results, published in The Lancet Infectious Diseases, revealed that ETVAX was safe, well-tolerated, and capable of eliciting a strong immune response against the bacteria.
Understanding how ETEC causes illness helps explain the vaccine’s design. The bacteria use specialized proteins called adhesins to latch onto the lining of the intestines. Once attached, they release toxins that cause watery diarrhea and abdominal pain. Poor sanitation and limited access to clean water in low-income settings increase the likelihood of exposure to these pathogens, exacerbating the burden of disease in vulnerable communities.
Prior to ETVAX, there was no approved vaccine specifically targeting ETEC infections. Some oral cholera vaccines, such as Dukoral, offered partial protection against certain types of ETEC diarrhea, but none provided comprehensive immunity. According to immunologist Ann-Mari Svennerholm from the University of Gothenburg, Sweden, who co-authored the Gambian study, ETVAX is the first vaccine to demonstrate significant protection against pathogenic E. coli infections in humans.
One of the challenges in developing an ETEC vaccine lies in the diversity of the bacteria. ETEC strains express a wide variety of adhesin proteins—26 different types in total—and produce two main types of toxins. To overcome this complexity, the creators of ETVAX formulated the vaccine to include the four most common adhesin proteins, which are present in about 80 percent of all ETEC strains. These proteins were combined with a harmless part of one toxin and a component designed to stimulate immune responses in the intestines. The vaccine was developed by Scandinavian Biopharma, and some authors of the study hold commercial rights, potentially receiving royalties if the vaccine becomes widely used.
Previous smaller studies in countries like Bangladesh and Zambia had already suggested that ETVAX was safe and effective in children, but the Gambian trial provided the most robust evidence to date. In this randomized, placebo-controlled study, children received three doses of either the vaccine or a placebo, with follow-up monitoring over two years. The double-blind design ensured that neither the researchers nor participants knew who received the vaccine, allowing for unbiased assessment of outcomes.
The immune response induced by ETVAX was promising. After the third dose, children showed increased antibody levels against multiple ETEC adhesin proteins. The vaccine reduced episodes of moderate-to-severe diarrhea caused by ETEC by 26 percent when cases involving co-infections with other common gut pathogens were excluded. These co-infections include viruses and bacteria such as Shigella, Cryptosporidium, rotavirus, and certain noroviruses, which often complicate diarrheal illnesses.
When including cases where co-infections were present, the vaccine’s efficacy was even more striking. ETVAX reduced moderate-to-severe diarrheal episodes from ETEC by 48 percent in all children and by an impressive 68 percent among infants younger than nine months. This finding underscores the critical importance of vaccinating infants early, before they develop natural immunity through exposure. Additionally, the vaccine appeared to confer some degree of cross-protection, reducing moderate-to-severe diarrhea caused by other gut pathogens by 21 percent. This suggests that ETVAX might help protect against a broader spectrum of diarrheal diseases beyond just ETEC.
Experts in the field have praised the quality of the study. David Sack, an